Adults
- Women after the age of 65;
- Women during menopause, if risk factors of fracturing exist (for instance, decreased body mass index, a history of “bristle bone” fracture, etc.)
- Men after the age of 70;
- Men prior to the age of 70, if risk factors of fracturing exist (for instance, decreased body mass index, a history of “bristle bone” fracture, etc.)
- Adults, who have sustained bone fractures in the event of minimal trauma;
- Adults, who have a disease or a health condition that is associated with reduced bone mass or loss of bone tissue, or who use medications associated with reduced bone mass or loss of bone tissue;
- Any patient prior to the commencement of specific osteoporosis therapy or after therapy to assess the effect caused by the therapy;
- Any patient, who has encountered rapid loss of bone mass (for instance, as a result of glucocorticoid use);
- Women, who have discontinued hormone replacement therapy (HRT);
- Any patient, who is not treated, but who would receive therapy, if the loss of bone mass is detected.
Children
- After long term (>1 year), systemic use of glucocorticoids;
- In the event of a chronic inflammatory disease (for instance, Crohn's disease, coeliac disease, ulcers, arthritis, systemic lupus erythematosus, dermatomyositis and other systemic diseases);
- In the event of hypogonadism;
- In the event of long-term immobilisation (>2 months);
- In the event of repeated fractures caused by minor trauma;
- If osteopenia is detected in a traditional radiological examination.
